Y. van Delft

发表

Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two‐way crossover trial

H. Crauwels, T. Kakuda, R. Hoetelmans, 2014, Journal of clinical pharmacology.

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.

P. Kaleebu, A. Siika, B. Castelnuovo, 2022, The lancet. HIV.

Research letter: is monitoring for CD4 counts still needed for the management of patients with long-term HIV RNA suppression?

C. Stephan, N. Xi, A. Hill, 2012, Journal of acquired immune deficiency syndromes.

No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial

S. Lewin, J. Arribas, A. Hill, 2014, PloS one.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?

D. Ripamonti, A. Hill, C. Moecklinghoff, 2013, AIDS reviews.

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

A. Horban, N. Clumeck, G. Fätkenheuer, 2010, AIDS.

Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study

A. Winston, A. Hill, G. Fätkenheuer, 2010, HIV clinical trials.

LETTERS TO THE EDITOR HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme Sirs: The next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (formerly known as TMC125) has shown e

S. De Wit, E. Ribera, A. Castagna, 2010 .

Interpretation of resistance data from randomized trials of first-line antiretroviral treatment.

B. Clotet, Ravindra K. Gupta, A. Hill, 2012, AIDS reviews.

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results

B. Gazzard, A. Castagna, A. Hill, 2011, AIDS.

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.

A. Rieger, N. Clumeck, J. Arribas, 2011, The Journal of antimicrobial chemotherapy.

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

B. Gazzard, D. Podzamczer, H. Stellbrink, 2011, AIDS.

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

S. De Wit, E. Ribera, A. Castagna, 2010, International journal of STD & AIDS.

Analysis of Drug Resistance during HIV RNA Viraemia in the Monet Trial of Darunavir/Ritonavir Monotherapy

J. Arribas, A. Hill, F. Pulido, 2011, Antiviral therapy.

Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.

J. Arribas, N. Xi, A. Hill, 2012, The Journal of antimicrobial chemotherapy.

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL

A. Antinori, A. Horban, J. Fehr, 2014, Journal of the International AIDS Society.

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV

L. Mohapi, E. Were, A. Avihingsanon, 2019, Southern African journal of HIV medicine.

Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients

M. Kurowski, M. Bickel, G. di Perri, 2013, HIV clinical trials.

Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.

M. Loutfy, S. De Wit, E. Ribera, 2009, The Journal of antimicrobial chemotherapy.

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.

A. Geretti, J. Vingerhoets, A. Hill, 2014, The Journal of antimicrobial chemotherapy.

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

A. Geretti, R. Demasi, Y. van Delft, 2015, AIDS research and treatment.

Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?

M. Nelson, A. Hill, P. Girard, 2013, AIDS.

Impact of hepatitis C co-infection on response to antiretroviral treatment.

A. Hill, F. Pulido, C. Moecklinghoff, 2012, AIDS reviews.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.

J. Arribas, A. Geretti, A. Hill, 2012, HIV clinical trials.

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

D. Podzamczer, C. Katlama, H. Furrer, 2012, The Journal of antimicrobial chemotherapy.

Performance of the Abbott RealTime HIV-1 assay versus the roche amplicor HIV-1 MonitorTM Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers.

C. Stephan, A. Hill, C. Moecklinghoff, 2014, The Journal of antimicrobial chemotherapy.

The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients

B. Gazzard, S. Esser, S. Rugină, 2010, Journal of the International AIDS Society.

Dynamics of Cellular HIV-1 DNA Levels Over 144 Weeks of Darunavir/Ritonavir Monotherapy Versus Triple Therapy in the MONET Trial

J. Arribas, A. Geretti, A. Hill, 2013 .

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

M. Nelson, A. Hill, C. Moecklinghoff, 2014, AIDS research and treatment.

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.

A. Rieger, N. Clumeck, J. Arribas, 2011, The Journal of antimicrobial chemotherapy.